Table 3.
Clinical features
| Clinicopathologic Parameters | Values |
|---|---|
| Patient Age At Diagnosis (years) | |
| Mean | 67.8 |
| Median | 67 |
| Range | 50-85 |
|
| |
| Surgical/Pathologic Stage Distribution | |
| IA | 17 |
| IB | 1 |
| II | 8 |
| IIIA | 6 |
| IIIB | 1 |
| IIIC | 7 |
| IV* | 9 |
| 1A (pT0: no residual malignancy in resection) | 1 |
|
| |
| Lymphadenectomy | |
| Only pelvic lymph nodes obtained | 10 |
| Only paraaortic lymph nodes obtained | 0 |
| Both pelvic and paraaortic lymph nodes obtained | 23 |
| No lymph nodes obtained | 7 |
| Lymphadenectomy status unknown | 10 |
| Lymph nodes positive for metastatic carcinoma | 10 |
| Pelvic nodes only positive | 6 |
| Paraaortic nodes only positive | 2 |
| Both pelvic and paraortic lymph nodes positive | 2 |
|
| |
| Treatment | |
| Chemotherapy only (no surgery) | 1 |
| Neoadjuvant chemotherapy, SR, adjuvant chemotherapy | 1 |
| TH/BSO with adjuvant chemotherapy and EBRT | 3 |
| TH/BSO with adjuvant chemotherapy and EBRT and VBT | 0 |
| TH/BSO with adjuvant chemotherapy and VBT | 6 |
| TH/BSO with VBT and EBRT | 3 |
| TH/BSO with VBT only | 2 |
| TH/BSO with EBRT only | 7 |
| TH/BSO with adjuvant chemotherapy only | 10 |
| TH/BSO without further treatment | 7 |
| Unknown | 10 |
|
| |
| Follow-up | |
| Number with follow up | 43 |
| Follow-up duration, Median/Mean/Range (months) | 31/21/1-104 |
| No evidence of Disease | 25 |
| Dead of Disease | 9 |
| Alive with Disease | 8 |
| Dead of other causes | 1 |
| Number of cases with recurrences/relapses | 11 |
|
| |
| Recurrences/Relapses | |
| Number of patients with recurrences/relapses | 11 |
| Duration to relapse | 1-27 months (mean 11.2 months) |
| Original Stage distribution for cases with relapses | III (n=8), I (n=2), II (n=1) |
| Relapse sites | Vagina (n=2), pleura, inguinal/groin region (n=2), supraclavicular lymph node, kidney, bone (n=2), abdominal soft tissue, lungs |
Stage assigned by FIGO (international Federation of Gynecology and Obstetrics criteria); TNM designation pT0 (assigned by 2009 American Joint Cancer Committee criteria);
*
Stage in one case (a stage IV patient ) was assigned clinically; TH/BSO: total hysterectomy and bilateral salpingo-oophorectomy; VBT vaginal cuff brachytherapy; EBRT external beam radiotherapy.